Skip to content
Home/Companies/Biotech/AdvanCell
AD

AdvanCell

Biotech·Australia·Active·1yr hold

AdvanCell is a biotech company, headquartered in Australia.

Entry
2025
Hold
1yr
Status
Active
Est. EV
–

Who owns AdvanCell?

AdvanCell is currently owned by Abingworth through Abingworth Bioventures 8 (2021 vintage), since 2025.

Hand-verified · updated 2026-06-07

Abingworth
Investor
Abingworth
Abingworth Bioventures 8 · 2021 · Life Sciences VC

Key facts

HQAustralia
SectorBiotech
StatusActive

More from Abingworth Bioventures 8

Other portfolio companies in the same fund.

Cytospire Therapeutics
Active
BiotechUK· 2026
Antares Therapeutics
Active
BiotechUS· 2025
Solve Therapeutics
Active
BiotechUS· 2025
Timberlyne Therapeutics
Active
HealthcareUS· 2025
Myricx Bio
Active
BiotechUK· 2024
Ascend Gene & Cell Therapies
Active
BiotechUK· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

GenSight Biologics
Active
Sofinnova PartnersFrance
InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
Data refreshed weekly · Sourced from public filings